在患有局部晚期或远程转移性差异化甲状腺癌的患者中融合瘤基因
Gaoda Ju1,2,3,4, Yuqing Sun2,3, Hao Wang5
1Department of Medical Oncology, Key Laboratory of Carcinogenesis & Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital and Institute, Beijing, 100142, China.
The Journal of clinical endocrinology and metabolism
|August 25, 2023
概括
融合瘤基因在儿科分化甲状腺癌 (DTC) 中更常见,并且与放射性 (RAI) 折射性有关. 在成年人中,TERT突变,而不是融合,是高级DTC中RAI折射性的主要驱动因素.
科学领域:
- 在瘤学瘤学.
- 遗传学 是一个遗传学.
- 分子生物学分子生物学
背景情况:
- 融合瘤基因是晚期差异化甲状腺癌 (DTC) 的关键驱动因素,经常导致对放射性 (RAI) 治疗的耐药性.
- 了解这些基因变异在不同患者群体中的特定作用对于有针对性的治疗策略至关重要.
研究的目的:
- 为了研究融合瘤基因与临床病理特征之间的关联,在一个大队伍的高级分化甲状腺癌 (DTC) 患者.
- 确定融合瘤基因 (RET,NTRK,ALK) 的患病率及其与患者年龄,瘤阶段和放射性 (RAI) 折射率的相关性.
主要方法:
- 使用26个基因小组 (ThyroLead) 进行了针对性下一代测序,对来自局部晚期或转移性DTC患者的278个瘤样本进行了测序.
- 临床病理学数据,包括美国癌症联合委员会 (AJCC) 的分期和放射性 (RAI) 折射性,与已识别的融合瘤基因相关分析.
主要成果:
- 在29.86%的晚期DTC病例中发现了融合瘤基因,儿童患者的患病率更高 (OR 2.411).
- 融合瘤基因与更先进的AJCC N和M阶段相关,并与儿科RAI折射性相关 (OR 4.85).
- 在成人DTC中,TERT突变是RAI折射性的主导因素 (OR 7.36),融合瘤基因显示较少的关联 (OR 0.50).
结论:
- 融合瘤基因在儿科DTC中更为普遍,并且与RAI折射性有关.
- TERT突变,而不是融合瘤基因,是成人高级DTC中RAI折射性的主要遗传驱动因素.
- 这些发现突出了差异化甲状腺癌中RAI折射性的特定年龄的遗传驱动因素,为个性化治疗方法提供了信息.
相关概念视频
01:33Cancer-Critical Genes I: Proto-oncogenes
9.0K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
9.0K
02:57Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
7.5K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
7.5K
02:38Mitogens and the Cell Cycle
6.6K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K
02:30Metastasis
5.6K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.6K
01:27Tumor Immunotherapy
556
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
556